Benjamin L. Ebert, MD, PhD (Dana-Farber Cancer Institute)Cancer Cell Biology, Cancer Risk, Prevention, and Early Detection, Leukemia
450 Brookline Avenue,
Dana Building, 16th Floor,
Boston, MA 02115
Richard M. Stone, MD (Dana-Farber Cancer Institute)Developmental Therapeutics, Leukemia
450 Brookline Avenue, Mayer 1B-17
Boston, MA 02215
DF/HCC Myeloid Malignancies Specialized Program of Research Excellence (SPORE)
The overall goal of this SPORE in Myeloid Malignancies is to take advantage of our increased understanding of the genetic and molecular basis of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to develop novel, effective therapeutic strategies for patients with these treatment-resistant neoplasms. The extensive scientific and clinical resources at the DF/HCC will be leveraged – marshaling local expertise in cell and molecular biology, genetics, immunology, biostatistics, chemistry, murine models, and clinical trial development – in order to perform innovative pre-clinical studies, to validate novel drug targets in patient cells, and to design and implement clinical trials that will eventually lead to improved outcomes for patients with myeloid malignancies.
The DF/HCC Myeloid Malignancies SPORE features four projects, four cores, a developmental research program and a career enhancement program.
If you are interested in becoming involved in the Myeloid Malignancies SPORE program, please contact: